GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist ...

Respiratory Virus Hospitalization Surveillance Network (RESP-NET) is made up of three networks that monitor COVID-19, ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Respiratory viruses can remain hidden in immune cells in the lungs long after the initial symptoms of an infection have ...

Immunization appointments are now open for eligible Albertans. As of Monday (Oct. 7) both COVID-19 and influenza immunization ...

Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.

GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...

All infants are to be offered a vaccine against the respiratory syncytial (RS) virus from next year to cut the number of ...

Illness from RSV is considered an infectious disease, usually leading to an infection of the upper respiratory tract but ...